Diyuan Xue

Diyuan Xue

Auto-generated profile, based on publicly available information

Diyuan Xue

Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China 3

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Science Immunology
Verified
Journal Article
Closed access
DXDiyuan Xue
Diyuan Xue
BMBenjamin Moon
Benjamin Moon
JLJing Liao
Jing Liao
JGJingya Guo
Jingya Guo
ZZZhuangzhi Zou
Zhuangzhi Zou
HPHua Peng
Hua Peng
A tumor-specific pro-IL-12 rejuvenated preexisting TILs to induce tumor growth delay without inducing systemic toxicity.

27 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJiao Shen
Jiao Shen
ZZZhuangzhi Zou
Zhuangzhi Zou
JGJingya Guo
Jingya Guo
YCYueqi Cai
Yueqi Cai
DXDiyuan Xue
Diyuan Xue
YFYang-Xin Fu
Yang-Xin Fu
Checkpoint blockade immunotherapy releases the inhibition of tumor-infiltrating lymphocytes (TILs) but weakly induces TIL proliferation. Exogenous IL-15 could further expand TILs and thus synergize with αPD-L1 therapy. However, systemic delivery of IL-15 extensively expands peripheral NK cells, causing severe toxicity. To redirect IL-15 to intratumoral PD-1+CD8+T effector cells instead of NK cells for better tumor control and lower toxicity, we engineered an anti–PD-1 fusion with IL-15-IL-15Rα, whose activity was geographically concealed by immunoglobulin Fc region with an engineered linker (αPD-1-IL-15-R) to bypass systemic NK cells. Systematic administration of αPD-1-IL-15-R elicited extraordinary antitumor efficacy with undetectable toxicity. Mechanistically, cis-delivery of αPD-1-IL-15-R vastly expands tumor-specific CD8+T cells for tumor rejection. Additionally, αPD-1-IL-15-R upregulated PD-1 and IL-15Rβ on T cells to create a feedforward activation loop, thus rejuvenating TILs, not only resulting in tumor control in situ, but also suppressing tumor metastasis. Collectively, renavigating IL-15 to tumor-specific PD-1+CD8+T cells, αPD-1-IL-15-R elicits effective systemic antitumor immunity.